文献速递泌尿男性生殖肿瘤

基于人群的前列腺癌筛查:磁共振成像或超声检查——IP1-PROSTAGRAM研究

Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study.
PubMed 文献 · JAMA Oncol · 2021-01-01

该前瞻性、基于人群的盲法队列研究纳入408名50-69岁男性,比较PSA、MRI和超声作为前列腺癌筛查试验的性能。MRI评分4-5分与PSA≥3 μg/L相比,诊断更多临床显著癌且不增加活检建议或过度诊断,超声未见优于PSA。

要点

  • MRI评分4-5分筛查可检出更多临床显著癌(11例 vs PSA 7例)。
  • MRI评分4-5分不增加活检建议人数或临床不显著癌检出。
  • 超声检查未见优于单独PSA检测的性能。

核心结论

  • MRI以评分4或5定义为阳性相比PSA≥3 ng/mL,与更多临床显著癌诊断相关,且不增加活检建议人数或过度诊断临床不显著癌。
  • 没有证据表明超声检查相比单独PSA检测有更好性能。

研究设计与样本

  • 前瞻性、基于人群的盲法队列研究,在英国7个初级保健机构和2个影像中心进行。
  • 邀请50至69岁男性参与筛查,共2034名受邀,411名参加筛查,408名同意接受所有筛查试验。

主要发现

  • MRI评分3-5分阳性比例为17.7%(95% CI 14.3%-21.8%),高于PSA≥3 μg/L的9.9%(95% CI 7.3%-13.2%),P < .001。
  • 超声评分3-5分阳性比例为23.7%(95% CI 19.8%-28.1%),高于PSA≥3 μg/L,P < .001。
  • MRI评分4-5分阳性比例为10.6%(95% CI 7.9%-14.0%),与PSA阳性比例相似,P = .71。
  • 超声评分4-5分阳性比例为12.8%(95% CI 9.9%-16.5%),与PSA阳性比例相似,P = .15。
  • PSA≥3 ng/mL检出7例临床显著癌,MRI评分3-5分检出14例,MRI评分4-5分检出11例,超声评分3-5分检出9例,超声评分4-5分检出4例。

关键数值与推荐

  • MRI阳性定义为评分3-5或4-5;PSA阳性定义为≥3 μg/L;超声阳性定义为评分3-5或4-5。
  • 临床显著癌定义为任何Gleason评分3+4或更高。
  • 若任何试验结果阳性,进行系统12针活检;若MRI或超声阳性,额外进行图像融合靶向活检。

临床怎么用

  • 在一般人群前列腺癌筛查中,可考虑使用MRI评分4-5分作为阳性阈值,相比PSA≥3 ng/mL可检出更多临床显著癌而不增加活检建议或过度诊断。
  • 超声检查不作为优于PSA的筛查工具推荐。

局限性

  • 研究仅纳入参加筛查的411名男性,样本量较小。
  • 筛查人群为50-69岁男性,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Screening for prostate cancer using prostate-specific antigen (PSA) testing can lead to problems of underdiagnosis and overdiagnosis. Short, noncontrast magnetic resonance imaging (MRI) or transrectal ultrasonography might overcome these limitations. OBJECTIVE: To compare the performance of PSA testing, MRI, and ultrasonography as screening tests for prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: This prospective, population-based, blinded cohort study was conducted at 7 primary care practices and 2 imaging centers in the United Kingdom. Men 50 to 69 years of age were invited for prostate cancer screening from October 10, 2018, to May 15, 2019. INTERVENTIONS: All participants underwent screening with a PSA test, MRI (T2 weighted and diffusion), and ultrasonography (B-mode and shear wave elastography). The tests were independently interpreted without knowledge of other results. Both imaging tests were reported on a validated 5-point scale of suspicion. If any test result was positive, a systematic 12-core biopsy was performed. Additional image fusion-targeted biopsies were performed if the MRI or ultrasonography results were positive. MAIN OUTCOMES AND MEASURES: The main outcome was the proportion of men with positive MRI or ultrasonography (defined as a score of 3-5 or 4-5) or PSA test (defined as PSA ≥3 μg/L) results. Key secondary outcomes were the number of clinically significant and clinically insignificant cancers detected if each test was used exclusively. Clinically significant cancer was defined as any Gleason score of 3+4 or higher. RESULTS: A total of 2034 men were invited to participate; of 411 who attended screening, 408 consented to receive all screening tests. The proportion with positive MRI results (score, 3-5) was higher than the proportion with positive PSA test results (72 [17.7%; 95% CI, 14.3%-21.8%] vs 40 [9.9%; 95% CI, 7.3%-13.2%]; P < .001). The proportion with positive ultrasonography results (score, 3-5) was also higher than the proportion of those with positive PSA test results (96 [23.7%; 95% CI, 19.8%-28.1%]; P < .001). For an imaging threshold of score 4 to 5, the proportion with positive MRI results was similar to the proportion with positive PSA test results (43 [10.6%; 95% CI, 7.9%-14.0%]; P = .71), as was the proportion with positive ultrasonography results (52 [12.8%; 95% CI, 9.9%-16.5%]; P = .15). The PSA test (≥3 ng/mL) detected 7 clinically significant cancers, an MRI score of 3 to 5 detected 14 cancers, an MRI score of 4 to 5 detected 11 cancers, an ultrasonography score of 3 to 5 detected 9 cancer, and an ultrasonography score of 4 to 5 detected 4 cancers. Clinically insignificant cancers were diagnosed by PSA testing in 6 cases, by an MRI score of 3 to 5 in 7 cases, an MRI score of 4 to 5 in 5 cases, an ultrasonography score of 3 to 5 in 13 cases, and an ultrasonography score of 4 to 5 in 7 cases. CONCLUSIONS AND RELEVANCE: In this cohort study, when screening the general population for prostate cancer, MRI using a score of 4 or 5 to define a positive test result compared with PSA alone at 3 ng/mL or higher was associated with more men diagnosed with clinically significant cancer, without an increase in the number of men advised to undergo biopsy or overdiagnosed with clinically insignificant cancer. There was no evidence that ultrasonography would have better performance compared with PSA testing alone.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Eldred-Evans D, Burak P, Connor MJ, et al. Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study. JAMA Oncol. 2021. PMID: 33570542. doi:10.1001/jamaoncol.2020.7456

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。